EcoDrugPlus

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSFHEG00000010721
Gene Symbol: BCR
3 Cross references
209 Possible Orthologues:

Bdnf/nt-3 Growth Factors Receptor-Like

Ensembl ID : ENSFHEG00000022643
Gene Symbol: LOC105938148
3 Cross references
210 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSFHEG00000014022
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSFHEG00000021564
Gene Symbol: LOC105920288
3 Cross references
190 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSFHEG00000005073
Gene Symbol: CCR9
3 Cross references
194 Possible Orthologues:

C-X-C Chemokine Receptor Type 4

Ensembl ID : ENSFHEG00000011069
Gene Symbol: LOC105919245
3 Cross references
216 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSFHEG00000007288
Gene Symbol: CXCR1
3 Cross references
275 Possible Orthologues:

C-Reactive Protein

Ensembl ID : ENSFHEG00000015021
Gene Symbol: LOC105929719
2 Cross references
384 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSFHEG00000017477
Gene Symbol: LOC105926390
2 Cross references
356 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSFHEG00000017487
Gene Symbol: LOC105926389
2 Cross references
356 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSFHEG00000009671
Gene Symbol: CFTR
2 Cross references
215 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSFHEG00000016236
Gene Symbol: LOC105938824
3 Cross references
175 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).